title: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
abstract: OBJECTIVE
  This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
  
  
  METHODS
  Patients had stage IIB, III, or IV disease or had stages I to IIA disease with bulky disease or other adverse features. Radiotherapy was administered in both arms to sites of previous bulk (> 5 cm) and to splenic deposits, although this was omitted in the latter part of the trial for patients achieving complete remission (CR) in the ABVD arm. A total of 520 patients were randomly assigned and were assessed for the primary outcome measure of progression-free survival (PFS). Five hundred patients received protocol treatment, and radiotherapy was administered to 73% in the Stanford V arm and to 53% in the ABVD arm.
  
  
  RESULTS
  The overall response rates after completion of all treatment were 91% for Stanford V and 92% for ABVD. During a median follow-up of 4.3 years, there was no evidence of a difference in projected 5-year PFS and overall survival (OS) rates (76% and 90%, respectively, for ABVD; 74% and 92%, respectively, for Stanford V). More pulmonary toxicity was reported for ABVD, whereas other toxicities were more frequent with Stanford V.
  
  
  CONCLUSIONS
  In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy.
authors.affiliation: Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Rd, Northwood, Middlesex HA6 2RN, United Kingdom. peterhoskin@nhs.net
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Hoskin
authors.forename: Lisa
authors.initials: L
authors.lastname: Lowry
authors.forename: Alan
authors.initials: A
authors.lastname: Horwich
authors.forename: Andrew
authors.initials: A
authors.lastname: Jack
authors.forename: Ben
authors.initials: B
authors.lastname: Mead
authors.forename: Barry W
authors.initials: BW
authors.lastname: Hancock
authors.forename: Paul
authors.initials: P
authors.lastname: Smith
authors.forename: Wendi
authors.initials: W
authors.lastname: Qian
authors.forename: Philippa
authors.initials: P
authors.lastname: Patrick
authors.forename: Bilyana
authors.initials: B
authors.lastname: Popova
authors.forename: Andrew
authors.initials: A
authors.lastname: Pettitt
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
authors.forename: Ruth
authors.initials: R
authors.lastname: Pettengell
authors.forename: John
authors.initials: J
authors.lastname: Sweetenham
authors.forename: David
authors.initials: D
authors.lastname: Linch
authors.forename: Peter W M
authors.initials: PW
authors.lastname: Johnson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin